Currently out of the existing stock ratings of Vincent Chen, 9 are a HOLD (52.94%), 8 are a BUY (47.06%).

Vincent Chen

Work Performance Price Targets & Ratings Chart

Analyst Vincent Chen, carries an average stock price target met ratio of 85% that have a potential upside of 17.14% achieved within 390 days. Previously, Vincent Chen worked at BERNSTEIN.

Vincent Chen’s has documented 33 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 23-Mar-2021.

Wall Street Analyst Vincent Chen

Analyst best performing recommendations are on ALNY (ALNYLAM PHARMACEUTICALS).
The best stock recommendation documented was for IONS (IONIS PHARMACEUTICALS) at 2/20/2018. The price target of $55 was fulfilled within 21 days with a profit of $5.01 (10.02%) receiving and performance score of 4.77.

Average potential price target upside

of $266.26 (17.27%) on BLUE (BLUEBIRD BIO).
of $23.04 (17.27%) on SRPT (SAREPTA THERAPEUTICS).
of $20.69 (21.89%) on ALNY (ALNYLAM PHARMACEUTICALS).

IONS Ionis Pharmaceuticals BLUE Bluebird bio ALNY Alnylam Pharmaceuticals BMRN Biomarin Pharmaceutical ONCE Spark Therapeutics RARE Ultragenyx SRPT Sarepta Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

David Lebowitz (BMO)